Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07861971
Recruiting Observational

Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission

NCT07861971 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-08-03
Last updated
2026-10-06

Condition(s) studied

Solid and Hematologic Cancer

Study summary

This is a single-center, non-randomized feasibility study. For this study, 19 young adults treated for cancer at the Paoli-Calmettes Institute will be included.This study includes interviews and questionnaires to assess the adherence rate. It will be measured by the percentage of patients who attend the first two coaching sessions (either in person or via videoconference) relative to the total number of patients included in the study.

The invitation to participate in this program will be made by the surgeon, hematologist, oncologist, or radiation therapist.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female aged 18 to 25 at the time of cancer diagnosis and/or at the time of inclusion. * In complete remission, within one year following the end of treatment and at the time of inclusion. * Treated at the Comprehensive Cancer Center Institut Paoli-Calmettes. * Able to speak and write in French. * Has not objected to participation in the study. * Affiliated with a social security scheme or beneficiary of such a scheme. Non -Inclusion Criteria: * Patient undergoing treatment, except for maintenance therapy. * Patient experiencing a relapse. * Person in an emergency situation, legally protected adult (under guardianship, curatorship, or judicial protection), or unable to express non-opposition. * Patient with clinically confirmed psychological symptoms (e.g., receiving antidepressants, mood stabilizers, anxiolytics, etc.). * Inability to comply with study follow-up due to geographic, social, or psychological reasons. Exclusion Criteria: Relapse occurring between inclusion and the second onco-coaching session.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institut Paoli-Calmettes Marseille France Recruiting

More Institut Paoli-Calmettes trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07861971 on ClinicalTrials.gov ↗ ← All trials in France